Ixazomib: First global approval

Drugs

Volumn 76, Issue 3, 2016, Pages 405-411

  Shirley, Matt ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

IXAZOMIB; PLACEBO; PROTEASOME; ANTINEOPLASTIC AGENT; BORON DERIVATIVE; GLYCINE; PROTEASOME INHIBITOR; PROTEIN BINDING; PSMB1 PROTEIN, HUMAN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DRUG HALF LIFE; DRUG POTENTIATION; FATIGUE; HUMAN; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; RASH; THROMBOCYTOPENIA; VOLUME OF DISTRIBUTION AT STEADY-STATE; VOMITING; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG APPROVAL; METABOLISM; MORTALITY; ORAL DRUG ADMINISTRATION; PRECLINICAL STUDY;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORON COMPOUNDS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; GLYCINE; HUMANS; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN BINDING;

EID: 84959098815     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-016-0548-5     Document Type: Article

References (30)

1. Moreau P, Touzeau C. Multiple myeloma: from front-line to relapsed therapies. Am Soc Clin Oncol Educ Book. 2015;35:e504-11.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Multiple myeloma (version 2.2016). 2015. http://www.nccn.org. Accessed 16 Dec 2015.
3. Kumar S. Implications of oral proteasome inhibition: impact on patients [abstract no. PS-029]. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl 3):e14-5.
4. Millennium Pharmaceuticals. Velcade® (bortezomib): prescribing information. 2015. http://www.velcade.com/. Accessed 16 Dec 2015.
5. Onyx Pharmaceuticals. Kyprolis® (carfilzomib): prescribing information. 2015. http://www.kyprolis.com/. Accessed 16 Dec 2015.
6. Moreau P. Oral therapy for multiple myeloma: ixazomib arriving soon. Blood. 2014;124(7):986-7.
7. US FDA. Ninlaro® (ixazomib) capsules: US prescribing information. 2015. http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/208462lbl.pdf. Accessed 16 Dec 2015.
8. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70(5):1970-80.
9. Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 Tourmaline-MM1 study (NCT01564537) [abstract no. 727]. In: 57th ASH Annual Meeting and Exposition. 2015.
10. US FDA. Ninlaro® (ixazomib) capsules: NDA approval. 2015. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2015/208462Orig1s000ltr.pdf. Accessed 16 Dec 2015.
11. European Medicines Agency. Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures. 2015. http://www.ema.europa.eu/ema/pages/includes/document/open-document.jsp?webContentId=WC500190953. Accessed 16 Dec 2015.
12. Takeda Pharmaceutical Company Ltd. Takeda announces European Medicines Agency acceptance of ixazomib's marketing authorization application for patients with relapsed/refractory multiple myeloma [media release]. 2015. http://www.takeda.com/news/2015/20150821-7104.html. Accessed 16 Dec 2015.
13. Takeda Pharmaceutical Company Ltd. Takeda's investigational, oral proteasome inhibitor ixazomib granted breakthrough therapy designation by U.S. FDA for relapsed or refractory systemic light-chain amyloidosis [media release]. 2015. http://www.takeda.com/news/2014/20141202-6830.html. Accessed 16 Dec 2015.
14. ClinicalTrials.org. Ixazomib clinical trials. 2015. http://clinicaltrials.gov/ct2/results?term=ixazomib&Search=Search. Accessed 16 Dec 2015.
15. Takeda Pharmaceutical Company Ltd. Takeda completes acquisition of Millennium [media release]. 2008. http://www.takeda.com/news/2008/20080515-3619.html. Accessed 16 Dec 2015.
16. Takeda Pharmaceutical Company Ltd. Takeda announces formalization of Takeda Oncology to enhance discovery, development and global commercialization of breakthrough cancer medicines [media release]. 2014. http://www.takeda.com/news/2014/20141208-6832.html. Accessed 16 Dec 2015.
17. Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311-21.
18. Lee EC, Fitzgerald M, Bannerman B, et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res. 2011;17(23):7313-23.
19. Dashnamoorthy R, Beheshti A, Abermil N, et al. Single agent activity and synergistic drug combinations of ixazomib in preclinical models of T-cell lymphoma (TCL) and Hodgkin lymphoma (HL) [abstract no. 278-P]. In: International Conference on Malignant Lymphoma. 2015.
20. Evens A, Dashnamoorthy R, Beheshti A, et al. Myc and Chk1 dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models with anti-proteasomal therapy [abstract no. 278]. Hematol Oncol. 2015;33:239.
21. Garcia-Gomez A, Quwaider D, Canavese M, et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease. Clin Cancer Res. 2014;20(6):1542-54.
22. Gupta N, Noe D, Liu G, et al. Clinical pharmacokinetics (PK) of intravenous (IV) and oral (PO) MLN9708, an investigational proteasome inhibitor: pooled analysis from monotherapy and combination studies across various indications [abstract no. PI-51]. Clin Pharmacol Ther. 2013;93(Suppl 1):S32.
23. Gupta N, Zhao Y, Hui AM, et al. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. Br J Clin Pharmacol. 2015;79(5):789-800.
24. Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124(7):1047-55.
25. Gupta N, Hanley MJ, Venkatakrishnan K, et al. A phase 1 study of the effect of a high-fat meal on the pharmacokinetics of ixazomib citrate (MLN9708), an investigational oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma [abstract no. P989]. Haematologica. 2014;99(Suppl 1):376.
26. Gupta N, Hanley MJ, Harvey RD, et al. Phase 1/1b pharmacokinetic (PK) and safety study of the investigational oral proteasome inhibitor (PI) ixazomib in relapsed/refractory multiple myeloma (RRMM) patients (Pts) with severe renal impairment or end-stage renal disease (ESRD) requiring hemodialysis [abstract no. 4227]. In: 57th ASH Annual Meeting and Exposition. 2015.
27. Gupta N, Hanley MJ, Venkatakrishnan K, et al. A phase 1 study to assess pharmacokinetics (PK) and safety of ixazomib, an oral proteasome inhibitor, in patients with moderate or severe hepatic impairment [abstract no. 3032]. In: 57th ASH Annual Meeting and Exposition. 2015.
28. Kumar S, Niesvizky R, Berdeja JG, et al. Safety and pharmacokinetics of weekly MLN9708, an investigational oral proteasome inhibitor, alone and in combination [abstract no. P-230]. Clin Lymphoma Myeloma Leuk. 2013;13(Suppl 1):S154.
29. Lonial S, Colson K, Harvey RD, et al. Safety profile of oral ixazomib: experience from 761 patients (pts) across 14 phase 1 or phase 1/2 clinical studies [abstract no. BP-056]. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl 3):e78-9.
30. Gupta N, Huh Y, Hutmacher MM, et al. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients. Cancer Chemother Pharmacol. 2015;76(3):507-16.